Screener Summaries Updates Institutions Sign In More Updates › Financing › SNDX Financing · Jun 4, 2026
Syndax Pharmaceuticals, Inc. entered into subscription agreements to issue $250.0 million of 2.25% Convertible Senior… SNDX Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. entered into subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031. The company expects net proceeds of approximately $243 million to be used for general corporate purposes, including research and development and commercialization. The notes feature an initial conversion price of approximately $24.76 per share.
More from Syndax Pharmaceuticals Inc Syndax Reports $83.3M Q3 Revenue; Appoints Aaron Ondrey as CFO Nov 2, 2026 Syndax Pharmaceuticals reported second quarter 2026 financial results ending June 30, 2026 Aug 4, 2026 Syndax Pharmaceuticals, Inc. held an R&D event on July 14, 2026, where it issued a press release and presentation… Jul 14, 2026 Syndax Pharmaceuticals, Inc. closed a private placement of $250.0 million in 2.25% Convertible Senior Notes due 2031… Jun 10, 2026 At its June 10, 2026 Annual Meeting, Syndax Pharmaceuticals stockholders approved the 2026 Equity Incentive Plan and… Jun 10, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
